A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)
Belatacept is a costimulatory blockade blocker, a mechanism of action different from that of current immunosuppressive medications. A previous study suggested it might allow for patients to be transplanted and not receive calcineurin inhibitors. This three-arm RCT compared two doses of belatacept to a conventional cyclosporine-based regimen. At one year, patient and graft survival and renal function were similar between the three groups, but there were more rejections with belatacept, and more patients who developed post-transplant lymphoproliferative disease. This study is planned to continue for another two years.